Missense variants in PTPN11 disrupt SHP2’s proper catalytic activity and the regulation of signaling pathways, leading to disorders such as Noonan syndrome (NS), LEOPARD syndrome (LS), or juvenile myelomonocytic leukemia (JMML). Here, PTPN11 is linked to Noonan syndrome with multiple lentigines.